Surrey, United Kingdom

Efamol Holdings Plc


USPTO Granted Patents = 20


Trademarks = 1

Forward Citations = 820

Loading Chart...
Loading Chart...

10 inventors (with patents filed for the assignee):

goldMedal David F Horrobin (17 out of 70 patents)

silverMedal John C Stewart (4 out of 7 patents)

bronzeMedal Yung-Sheng Huang (3 out of 4 patents)

4.  Raymond Bonnett (2 out of 3 patents)

5.  Morris C Berenbaum (2 out of 3 patents)

6.  Michael D Winther (2 out of 3 patents)

7.  Colin Bernard Reese (1 out of 8 patents)

8.  Frank Corrigan (1 out of 1 patent)

9.  Michael J Finnen (1 out of 1 patent)

10.  Alfred C Buck (1 out of 1 patent)

11.  John Charles Stewart (0 patent)

12.  David Frederick Horrobin (0 patent)


20 patents:

Company Overview
Efamol Holdings Plc is a prominent player in the health and wellness sector, specializing in the development and manufacturing of high-quality nutritional supplements. The company focuses on omega-3 fatty acids and other essential nutrients, catering to both consumer and professional markets. With a commitment to research and innovation, Efamol leverages advanced technology to enhance product efficacy and safety. Headquartered in Surrey, the company serves a global clientele, emphasizing the importance of nutritional health in everyday life.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

20 Patents

#9 in Surrey

#889 in United Kingdom

#31,233 in the World

Surrey, GB
Surrey, United Kingdom
Forward Citations = 820

10 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Efamol Holdings Plc. Retrieved from https://idiyas.com/company/efamol-holdings

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…